Sun Pharma的净利润年同比增长了2.52.6%,到Q2 FY26年达到3 118 克郎,其驱动因素是全球和印度的强劲销售增长,尽管美国的通用产品有所下降。 Sun Pharma's net profit rose 2.5%–2.6% year-on-year to ₹3,118 crore in Q2 FY26, driven by strong global and Indian sales growth, despite a U.S. generics decline.

Sun Pharma报告说,26财政年度第二季度的净利润年同比增长2.5%至2.6%,达到3 118克郎,收入增长8.6%至14 405克郎。 Sun Pharma reported a 2.5% to 2.6% year-on-year increase in net profit to ₹3,118 crore for the second quarter of FY26, with revenue rising 8.6% to ₹14,405 crore. 印度、新兴市场和世界其他地区的强劲表现推动了增长,印度的配方销售额增长了11%,全球创新药品销售额增长了16.4%,达到3.33亿美元。 Growth was driven by strong performance in India, emerging markets, and the Rest of World, with India’s formulation sales up 11% and global innovative medicines sales rising 16.4% to $333 million. 美国创新药品销售首次超过了非专利药品销售。 For the first time, innovative medicine sales in the U.S. exceeded generics. 尽管美国配方销售下降4.1%,但该公司推出了九种新产品,并推进了其研发管道,包括一个GLP-1候选人和临床试验中的六个新实体。 Despite a 4.1% decline in U.S. formulation sales, the company launched nine new products and advanced its R&D pipeline, including a GLP-1 candidate and six novel entities in clinical trials. API对外销售下降19.5%,而EBITDA公司则上升了14.9%,达到4,527克鲁尔,利润率为31.3%。 API external sales fell 19.5%, while EBITDA rose 14.9% to ₹4,527 crore, with margins at 31.3%.